Effects and safety of Ginkgo biloba on blood metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis.

Huimin Zou, Jingxian Fang, Yu Han, Xue Hu, Jian Meng, Fang Huang, Hui Xu, Chengfei Lu, Yiwen Wang, Lili Zhang, Xiaohong Dong, Yanmei Yu, Yu Guo, Qing Gu, Suijun Wang

Journal: Frontiers in endocrinology 2024;14():1231053

PMID: 38264278

Abstract

BACKGROUND

There has existed controversy regarding the use of Ginkgo biloba (GKB) for blood metabolism among type 2 diabetes mellitus(T2DM) patients, and we tried to analyze the effects and safety of GKB on T2DM patients.

METHODS

We conducted a literature search between January 2003 and December 2022 of seven online databases (PubMed, Scopus, Embase, Google Scholar, Web of Sciences, Cochrane Library, and China National Knowledge Infrastructure). A systematic literature review and meta-analysis were performed to compare the effects and safety of GKB among T2DM patients. Four groups of parameters were extracted and analyzed: hemorheology parameters, lipid profile, glycemic control markers, and adverse events.

RESULTS

In the end, 13 eligible articles with 11 indicators among 1573 patients were included. In the hemorheology parameters section, GKB showed significantly lower plasma viscosity (PV) (SMD=-0.91, 95%CI [-1.45, -0.36], <0.01) and hematocrit (Hct) (SMD=-0.60, 95%CI [-0.97, -0.24], <0.01) than the control group. GKB shoed higher velocity of the dorsalis pedis artery (VDPA) (SMD=0.51, 95%CI [0.26, 0.76], <0.01) and ankle brachial index (ABI) (SMD=0.71, 95%CI [0.32, 1.10], <0.01) than the control. In both the lipid profile and glycemic control markers sections, we did not find any difference between GKB and control groups, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), hemoglobin A1c (HbA1c), and fasting serum glucose (FSG). In addition, we saw no difference in adverse events (AE). The sensitivity analysis and funnel plot showed that the results in this research were robust and had no publication bias.

CONCLUSION

In conclusion, GKB might safely reduce the risk of peripheral arterial or even systemic cardiovascular disease. However, GKB did not directly improve lipid and blood glucose levels in T2DM patients.

SYSTEMATIC REVIEW REGISTRATION

https://inplasy.com/, identifier INPLASY202350096.

Copyright © 2024 Zou, Fang, Han, Hu, Meng, Huang, Xu, Lu, Wang, Zhang, Dong, Yu, Guo, Gu and Wang.

Address: Department of Endocrinology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.